Aim: Malnutrition is one of the most common complications in patients with liver cirrhosis. Abnormal energy substrate metabolism may contribute to aggravation of malnutrition. Late evening snack (LESs) supplementation has been recommended as an intervention to reduce starvation time and improve nutritional status. Published studies have analyzed the effect of LESs on the branched-chain amino acid (BCAA)/tyrosine ratio (BTR) and oxidation rate of fat and carbohydrate in patients with liver cirrhosis. Methods: We searched PubMed, Cochrane Library, Web of Science and Embase for relevant research from January 2000 to October 2018. The primary outcome for this analysis was changes in BTR and fat and carbohydrate oxidation in patients with liver cirrhosis. Results: A total of 9 articles, containing 211 patients, were included in this analysis. The results supported that supplementation with BCAA-enriched LESs improved BTR, and longterm supplementation with BCAAs (>1 month) may be more beneficial than short-term supplementation (<1 month) in patients with liver cirrhosis. In addition, supplementation with BCAAs may increase the oxidation rate of carbohydrates and decrease the oxidation rate of fat. Furthermore, compared with liquid-enriched LESs, BCAA was a better choice for increasing the oxidation of carbohydrates and decreasing the rate of fat oxidation. Conclusion: BCAA-enriched LES supplementation is an appropriate nutritional intervention to improve abnormal energy substrate metabolism, which may improve malnutrition in patients with liver cirrhosis. Further research is needed on the long-term benefit and improved survival in patients with liver cirrhosis.
Introduction
Malnutrition is one of the most common complications in patients with liver cirrhosis and is associated with an increased risk of morbidity and mortality. 1 As an important part of the comprehensive treatment of liver cirrhosis, nutritional intervention can help to improve the nutritional status and quality of life of patients with liver cirrhosis. 2 The liver is an important organ for maintaining normal energy and nutrient metabolism. Therefore, it is important to explore appropriate nutritional interventions for patients with liver cirrhosis. Abnormal energy substrate metabolism is characteristic of patients with liver cirrhosis, which may aggravate malnutrition. 3 In particular, after overnight fasting, patients with liver cirrhosis show increased rates of fat oxidation and decreased rates of carbohydrate oxidation compared to normal controls. In addition, previous studies on the correlation between lifestyle and liver disease have shown that lower daily frequency of meals is associated with nonalcoholic fatty liver disease, which is a risk factor for the development of liver cirrhosis, and a high daily eating frequency is associated with healthy lifestyle. 4, 5 Therefore, increasing the frequency of eating is used as intervention. Late evening snacks (LESs), which add an extra meal before sleep, has been recommended as an intervention to reduce the starvation time and improve nutritional status. 6, 7 LESs are currently an effective method to improve the metabolic status of patients with end-stage liver disease. 6 However, published studies have had small sample sizes. It is also unclear whether long-term intervention with LESs and whether branched-chain amino acids (BCAAs) are more suitable for patients with liver cirrhosis. In patients with liver cirrhosis, due to the decline in glycogen reserves and activated glutamine synthesis in muscle, the consumption of BCAAs increases, which can lead to an imbalanced ratio of BCAA to aromatic amino acids (AAAs). 8 Clinically, the BCAA/tyrosine ratio (BTR) reflects the ratio of BCAAs to AAAs, and changes are closely related to liver dysfunction. 9 Previous studies have shown that BTR is a prognostic factor for hepatocellular carcinoma. 10 In addition, the rate of fat and carbohydrate oxidation is closely related to prognosis of cirrhosis. 11 Therefore, this study summarizes the currently published literature that has analyzed the effects of LESs on BTR and the oxidation rate of fat and carbohydrate in patients with liver cirrhosis. It may provide evidence for the clinical application of LESs in patients with liver cirrhosis.
Material and methods

Study selection
This meta-analysis was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). 12 We selected articles 
Definition and study endpoints
Liver cirrhosis was diagnosed by clinical and laboratory profiles and by histological examination of liver biopsy specimens. 13 The primary endpoint of this study was whether BTR and oxidation rate of carbohydrate and fat were affected by LESs. Data extraction and quality assessment Two investigators (J.Y. and W.H.) extracted the following information from the selected researches independently: first author, year of publication, intervention of experimental group, total numbers of patients enrolled, time of intervention for each event, levels of BTR, and oxidation rate of carbohydrate and fat before and after intervention. When research on the same patients appeared in multiple articles, to avoid duplication of information, we selected the study with the largest sample.
The US Agency for Healthcare Research and Quality (AHRQ) was used to evaluate bias risks in each study.
Study eligibility
Inclusion criteria: liver cirrhosis was diagnosed on the basis of pathological examination findings and ChildPugh classification. Exclusion criteria: patients had a history of other organ diseases, such as chronic heart failure or chronic respiratory, pancreatic or renal diseases.
Statistical analysis
We used Review Manager 5.2 and Stata 12.0 software for statistical analysis. Differences were expressed as mean ± standard deviation with 95% CI. Heterogeneity was tested using the I 2 statistic. Heterogeneity was considered to be low in 
Results
Study selection and characteristics
The selection process is illustrated in Figure 1 . A total of 9 articles met the inclusion criteria. [14] [15] [16] [17] [18] [19] [20] [21] [22] The main characteristics of the included studies are described in Table 1 . The metaanalysis included 221 patients from Japan, aged 42-85 years.
One study was a randomized controlled trial (RCT) 18 and the others were single-arm studies. Three of the 9 studies supplied a pack of LESs (210 kcal), 14, 17, 22 others gave a pack of LESs and 1 or more supplements during the daytime. Three of the 9 studies used long-term LESs (>1 month) 14, 15, 17 and the others used short-term LESs. Six of the 9 studies reported changes in BTR [14] [15] [16] [17] 19, 21 and 5 reported changes in fat and carbohydrate oxidation.
18-22
Quality assessment
Although one study was an RCT, the baseline characteristics of each group were not comparable. We, therefore, compared the changes before and after LES treatment in each group, and we divided this RCT into 3 groups of one-arm study. Assessment of the single-arm studies by the AHRQ methodology checklist is shown in Table 2 .
All included single-arm studies described the source of data and patient inclusion and exclusion criteria clearly, provided detailed explanation for excluded data, and presented measurements for the primary study endpoints.
Effects of less on BTR
We selected 6 studies that measured the changes in BTR before and after LESs. 14 (Figure 2A ). In order to find the reason, subgroup analysis was performed by treatment period. Three of the studies had short-term LESs (<1 month) compared with >1 month in the others. BTR in the longterm LES group was increased with no heterogeneity (I 2 =0%), but BTR in the short-term LES group was increased with high heterogeneity (I 2 =96%) ( Figure 2B ). The differences between the groups were significant (P=0.02). The changes in BTR after long-term LESs were superior to that after short-term LESs.
In the long-term treatment subgroup, BACCs were given besides LESs in one study, 15 and BACCs were given once a day as LESs in 2 studies. 14,17 Subgroup analysis showed that BTR was increased in the two groups, but there was no difference between these 2 treatments (P=0.48) ( Figure 2C ). Analysis of sensitivity was conducted to evaluate the robustness of the effect. The results showed that sensitivity was low (MD=0.58, 95% CI [0.35, 0.81], the range for all articles was 95% CI [0.27, 0.93]). Begg's test showed publication bias in the 6 studies, although it was not significant (Pr > |z| =0.296, continuity corrected).
Effects of less on oxidation rate of fat
We selected 5 studies that measured changes in fat oxidation before and after LESs. [18] [19] [20] [21] [22] Fat oxidation was decreased after LESs (MD= −13.21, 95% CI [−15.34, −11.07]) with low heterogeneity (I 2 =23%) ( Figure 3A) . Patients in two studies 17, 22 were treated with a pack of liquid nutrients as LESs, and the others received a pack of BCAAs. Subgroup analysis showed that BCAAs and liquid nutrients decreased fat oxidation, although there was no significant difference between the 2 groups (P=0.15).
There was no heterogeneity in the BCAA group, but the heterogeneity in the liquid nutrient group was significant (I 2 =73%) ( Figure 3B ), so this was an important source of heterogeneity. The results indicated BCAA was a better choice for reducing the oxidation rate of fat. Analysis of sensitivity was conducted to evaluate the robustness of the effect. The results showed that sensitivity was low (mean estimate= −1.11, 95% CI [−1.42, −0.80]), and the range for all articles was 95% CI [−1.78, −0.65]). Begg's test showed publication bias in the 5 studies, although it was not significant (Pr > |z| =0.086, continuity corrected).
Effects of less on oxidation rate of carbohydrate
We selected 5 studies that measured the oxidation rate of carbohydrate before and after LESs. [18] [19] [20] [21] [22] Subgroup analysis showed that BCAAs and liquid nutrients both increased the oxidation rate of carbohydrate, although there was no significant difference between the two treatment groups (P=0.18). There was no heterogeneity in the BCAA group, but the heterogeneity in the liquid nutrient group was significant (I 2 =59%) ( Figure 4B ), so this was an important source of heterogeneity. The result indicated that BCAA was a better choice for increasing the oxidation rate of carbohydrate.
Analysis of sensitivity was conducted to evaluate the robustness of the effect. The results showed that sensitivity was low (MD=1.09, 95% CI [0.78, 1.4]), the range for all articles was 95% CI [0.63, 1.67]). Begg's test showed publication bias in the 5 studies, although it was not significant (Pr > |z| =0.086, continuity corrected).
Adverse effects of less
There were no adverse events related to LESs in any of the 9 articles.
Discussion
This study evaluated the published literature on the effects of LESs, especially BCAA-based LESs. The results of the analysis supported that supplementation with BCAAs can improve BTR, and long-term supplementation with BCAAs (>1 month) may be more beneficial than shortterm supplementation (<1 month) in patients with liver cirrhosis. In addition, supplementation with BCAAs may increase the oxidation rate of carbohydrates and decrease the oxidation rate of fat, thereby significantly improving abnormal energy substrate metabolism in patients with liver cirrhosis. LESs are one of the commonly used nutritional interventions, but there is a scarcity of high-quality research among published studies. The results of the present study may provide evidence for BCAAs as a major component of LESs to improve substrate metabolism in patients with liver cirrhosis.
Since the glycogen reserve of liver cells in patients with cirrhosis is less than that of normal people, short- 25 Similar to previous studies, the present study supports the idea that LESs may improve the oxidation rate of carbohydrates and reduce the oxidation rate of fat in patients with liver cirrhosis. Furthermore, the BCAAbased LESs are better than fat-based LESs for increasing carbohydrate oxidation rate and reducing fat oxidation rate. Therefore, BCAA is considered to be a good choice for LES intervention.
Patients with liver cirrhosis often have amino acid metabolism disorder, which is often associated with a variety of complications such as hepatic encephalopathy and sarcopenia.
14 Most studies have shown that BCAA supplementation improves amino acid profile, albumin level, and hepatic encephalopathy, 26 and may also promote regeneration of liver cells. 27 There is also research indicating that BCAAs can reduce the risk of liver cancer recurrence. 28 However, to date, there has been no large study on BCAA supplementation in patients with liver cirrhosis. A total of 9 studies were pooled in the present study. The results showed that in patients with liver cirrhosis, BTR was significantly higher after than before oral BCAA supplementation. More importantly, there has been no study on the duration of BCAA supplementation. We showed that long-term BCAA supplementation (>1 month) may be more beneficial than short-term supplementation (<1 month) in patients with liver cirrhosis. There were some limitations to this study, most of which were related to the quality of the research papers included. First, only 1 of the 9 studies was an RCT and the others were single-arm studies. Second, most of the studies had small samples. Third, most of the patients included in this study were Asians. Therefore, a large, multicenter RCT is needed to further analyze the effects of LESs, especially BCAAbased LESs, on patients with liver cirrhosis.
Conclusion
LESs based on BCAAs can improve BTR, increase the oxidation rate of carbohydrates, and decrease the oxidation rate of fat in patients with liver cirrhosis, which may improve the malnutrition in these patients. Long-term supplementation with BCAAs is more efficient and better than fat-based LESs. Our results may provide evidence for the clinical application of LESs in patients with liver cirrhosis. When patients are supplemented with BCAAs, one should also consider the individual choice of the patient and the detailed status of their condition. Therefore, further research requires a larger sample of more individualized and standardized treatments.
